News

GlobalData on MSN1mon
Atsena’s ATSN-201 gains FDA fast track status for XLRS treatment
This approach ensures the elimination of the surgical risks typically associated with foveal detachment ... which is ...
Ophthalmology Times13d
FDA grants RMAT designation to Atsena Therapeutics' gene therapy for XLRS
ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...
Pharmabiz13d
Atsena Therapeutics receives US FDA’s RMAT designation for ATSN-201 gene therapy to treat X-linked Retinoschisis
Durham, North Carolina Thursday, April 17, 2025, 12:00 Hrs [IST] ...
Business Insider1mon
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
XLRS is characterized by schisis, or abnormal splitting of retinal ... At clinically relevant doses, AAV.SPR efficiently transduces foveal cones without the need for surgical detachment and ...